Current therapy of drugs in amyotrophic lateral sclerosis

Current Neuropharmacology

Volumn 14, Issue 4, 2016, Pages 314-321

  Lu, Haiyan ^a   Le, Wei Dong ^b   Xie, Ya Ying ^a   Wang, Xiao Ping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Amyotrophic lateral sclerosis; Edaravone; Motor neuron disease; Neurodegenerative disease; Pyrimethamine; Riluzole; SOD1 mutations

Indexed keywords

2 (3 IODOPHENYL)METHYLSULFANYL) 5PYRIDIN 4 YL 1,3,4 OXADIAZOLE; AMPA RECEPTOR; AMYLOID PRECURSOR PROTEIN; BROMOCRIPTINE; COLECALCIFEROL; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOCHROME C; DIACETYL BIS(4 METHYLTHIOSEMICARBAZONATO) COPPER II COMPLEX; DIACETYL BIS(4 METHYLTHIOSEMICARBAZONATO) ZINC II COMPLEX; ERYTHROPOIETIN; GACYCLIDINE; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; GUANABENZ; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 2; MESSENGER RNA; NEUROKININ 1 RECEPTOR; NEURONAL APOPTOSIS INHIBITORY PROTEIN; NEUROTROPHIC FACTOR; OLESOXIME; PYRIMETHAMINE; REACTIVE OXYGEN METABOLITE; RILUZOLE; SIRTUIN 1; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VITAMIN D; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CHOLEST 4 EN 3 ONE; DASATINIB; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; SOD1 PROTEIN, HUMAN;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN STEM; CEREBROSPINAL FLUID; DRUG BINDING; EXCITOTOXICITY; GENE MUTATION; HUMAN; INFLAMMATION; MEDIAN SURVIVAL TIME; MITOCHONDRION; MOTONEURON; MOTOR CORTEX; NERVE CELL DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; SPINAL CORD; ANIMAL; DRUG EFFECTS; GENETICS; MOUSE; TREATMENT OUTCOME;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; APOPTOSIS; CHOLESTENONES; DASATINIB; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MICE; MITOCHONDRIA; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; RILUZOLE; SUPEROXIDE DISMUTASE-1; TREATMENT OUTCOME;

EID: 84964240797     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X14666160120152423     Document Type: Article

References (103)

1. Mulder, D.W.; Kurland, L.T.; Offord, K.P.; Beard, C.M. Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology, 1986, 36(4), 511-517. http://dx.doi.org/10.1212/WNL.36.4.511
2. Mitsumoto, H.; Przedborski, S.; Gordon, P.H. Amyotrophic lateral sclerosis. Taylor & Francis: New York, 2006.
3. Rowland, L.P. How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot. Arch. Neurol., 2001, 58(3), 512-515. http://dx.doi.org/10.1001/archneur.58.3.512
4. Gordon, P.H.; Cheng, B.; Katz, I.B.; Pinto, M.; Hays, A.P.; Mitsumoto, H.; Rowland, L.P. The natural history of primary lateral sclerosis. Neurology, 2006, 66(5), 647-653. http://dx.doi.org/10.1212/01.wnl.0000200962.94777.71
5. Rowland, L.P.; Shneider, N.A. Amyotrophic lateral sclerosis. N Engl. J. Med., 2001, 344(22), 1688-1700. http://dx.doi.org/10.1056/NEJM200105313442207
6. Neymotin, A.; Petri, S.; Calingasan, N.Y.; Wille, E.; Schafer, P.; Stewart, C.; Hensley, K.; Beal, M.F.; Kiaei, M. Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol., 2009, 220(1), 191-197. http://dx.doi.org/10.1016/j.expneurol.2009.08.028
7. Pandya, R.S.; Zhu, H.; Li, W.; Bowser, R.; Friedlander, R.M.; Wang, X. Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell Mol. Life Sci., 2013, 70(24), 4729-4745. http://dx.doi.org/10.1007/s00018-013-1415-0
8. Gordon, P.H. Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials. Aging Dis., 2013, 4(5), 295-310. http://dx.doi.org/10.14336/AD.2013.0400295
9. Rosen, D.R. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 1993, 364(6435), 362. http://dx.doi.org/10.1038/364362c0
10. Pratt, A.J.; Getzoff, E.D.; Perry, J.J. Amyotrophic lateral sclerosis: update and new developments. Degener. Neurol. Neuromuscul. Dis., 2012, 2012(2), 1-14. http://dx.doi.org/10.1038/364362c0
11. Boillee, S.; Yamanaka, K.; Lobsiger, C.S.; Copeland, N.G.; Jenkins, N.A.; Kassiotis, G.; Kollias, G.; Cleveland, D.W. Onset and progression in inherited ALS determined by motor neurons and microglia. Science, 2006, 312(5778), 1389-1392. http://dx.doi.org/10.1126/science.1123511
12. Lacomblez, L.; Bensimon, G.; Leigh, P.N.; Guillet, P.; Meininger, V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet, 1996, 347(9013), 1425-1431. http://dx.doi.org/10.1016/S0140-6736(96)91680-3
13. Logroscino, G.; Traynor, B.J.; Hardiman, O.; Chio, A.; Couratier, P.; Mitchell, J.D.; Swingler, R.J.; Beghi, E.; Eurals. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J. Neurol. Neurosurg. Psychiatry, 2008, 79(1), 6-11. http://dx.doi.org/10.1136/jnnp.2006.104828
14. Dunkel, P.; Chai, C.L.; Sperlagh, B.; Huleatt, P.B.; Matyus, P. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer’s, Parkinson’s and Huntington’s diseases, and amyotrophic lateral sclerosis. Expert Opin. Investig. Drugs, 2012, 21(9), 1267-1308. http://dx.doi.org/10.1517/13543784.2012.703178
15. Bensimon, G.; Lacomblez, L.; Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med., 1994, 330(9), 585-591. http://dx.doi.org/10.1056/NEJM199403033300901
16. Deng, Y.; Xu, Z.; Xu, B.; Tian, Y.; Xin, X.; Deng, X.; Gao, J. The protective effect of riluzole on manganese caused disruption of glutamate-glutamine cycle in rats. Brain Res., 2009, 1289, 106-117. http://dx.doi.org/10.1016/j.brainres.2009.07.012
17. Deflorio, C.; Onesti, E.; Lauro, C.; Tartaglia, G.; Giovannelli, A.; Limatola, C.; Inghilleri, M.; Grassi, F. Partial block by riluzole of muscle sodium channels in myotubes from amyotrophic lateral sclerosis patients. Neurol. Res. Int., 2014, 2014, 946073.
18. Borras-Blasco, J.; Plaza-Macias, I.; Navarro-Ruiz, A.; Peris-Marti, J.; Anton-Cano, A. Riluzole as a treatment for amyotrophic lateral sclerosis. Rev. Neurol., 1998, 27(160), 1021-1027.
19. Gurney, M.E.; Pu, H.; Chiu, A.Y.; Dal Canto, M.C.; Polchow, C.Y.; Alexander, D.D.; Caliendo, J.; Hentati, A.; Kwon, Y.W.; Deng, H.X., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science, 1994, 264(5166), 1772-1775. http://dx.doi.org/10.1126/science.8209258
20. Gurney, M.E. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J. Neurol. Sci., 1997, 152 Suppl 1, S67-73. http://dx.doi.org/10.1016/S0022-510X(97)00247-5
21. Foust, K.D.; Salazar, D.L.; Likhite, S.; Ferraiuolo, L.; Ditsworth, D.; Ilieva, H.; Meyer, K.; Schmelzer, L.; Braun, L.; Cleveland, D.W.; Kaspar, B.K. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther, 2013, 21(12), 2148-2159. http://dx.doi.org/10.1038/mt.2013.211
22. Thomsen, G.M.; Gowing, G.; Latter, J.; Chen, M.; Vit, J.P.; Staggenborg, K.; Avalos, P.; Alkaslasi, M.; Ferraiuolo, L.; Likhite, S.; Kaspar, B.K.; Svendsen, C.N. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J. Neurosci., 2014, 34(47), 15587-15600. http://dx.doi.org/10.1523/JNEUROSCI.2037-14.2014
23. Novoselov, S.S.; Mustill, W.J.; Gray, A.L.; Dick, J.R.; Kanuga, N.; Kalmar, B.; Greensmith, L.; Cheetham, M.E. Molecular chaperone mediated late-stage neuroprotection in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. PLoS One, 2013, 8(8), e73944. http://dx.doi.org/10.1371/journal.pone.0073944
24. Rabinovich-Toidman, P.; Rabinovich-Nikitin, I.; Ezra, A.; Barbiro, B.; Fogel, H.; Slutsky, I.; Solomon, B. Mutant SOD1 Increases APP Expression and Phosphorylation in Cellular and Animal Models of ALS. PLoS One, 2015, 10(11), e0143420.
25. Lukas, T.J.; Schiltz, G.E.; Arrat, H.; Scheidt, K.; Siddique, T. Discovery of 1,3,4-oxidiazole scaffold compounds as inhibitors of superoxide dismutase expression. Bioorg. Med. Chem. Lett., 2014, 24(6), 1532-1537. http://dx.doi.org/10.1016/j.bmcl.2014.01.078
26. McAllum, E.J.; Lim, N.K.; Hickey, J.L.; Paterson, B.M.; Donnelly, P.S.; Li, Q.X.; Liddell, J.R.; Barnham, K.J.; White, A.R.; Crouch, P.J. Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal. Degener., 2013, 14(7-8), 586-590. http://dx.doi.org/10.3109/21678421.2013.824000
27. McAllum, E.J.; Roberts, B.R.; Hickey, J.L.; Dang, T.N.; Grubman, A.; Donnelly, P.S.; Liddell, J.R.; White, A.R.; Crouch, P.J. Zn(II)(atsm) is protective in amyotrophic lateral sclerosis model mice via a copper delivery mechanism. Neurobiol. Dis., 2015, 81, 20-24. http://dx.doi.org/10.1016/j.nbd.2015.02.023
28. Miller, T.M.; Pestronk, A.; David, W.; Rothstein, J.; Simpson, E.; Appel, S.H.; Andres, P.L.; Mahoney, K.; Allred, P.; Alexander, K.; Ostrow, L.W.; Schoenfeld, D.; Macklin, E.A.; Norris, D.A.; Manousakis, G.; Crisp, M.; Smith, R.; Bennett, C.F.; Bishop, K.M.; Cudkowicz, M.E. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol., 2013, 12(5), 435-442. http://dx.doi.org/10.1016/S1474-4422(13)70061-9
29. Chen, T.; Benmohamed, R.; Kim, J.; Smith, K.; Amante, D.; Morimoto, R.I.; Kirsch, D.R.; Ferrante, R.J.; Silverman, R.B. ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis. J. Med. Chem., 2012, 55(1), 515-527. http://dx.doi.org/10.1021/jm2014277
30. Zhang, Y.; Zhao, K.T.; Fox, S.G.; Kim, J.; Kirsch, D.R.; Ferrante, R.J.; Morimoto, R.I.; Silverman, R.B. Tertiary Amine Pyrazolones and Their Salts as Inhibitors of Mutant Superoxide Dismutase 1- Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis. J. Med. Chem., 2015, 58(15), 5942-5949. http://dx.doi.org/10.1021/acs.jmedchem.5b00561
31. Ito, H.; Wate, R.; Zhang, J.; Ohnishi, S.; Kaneko, S.; Ito, H.; Nakano, S.; Kusaka, H. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol, 2008, 213(2), 448-455. http://dx.doi.org/10.1016/j.expneurol.2008.07.017
32. Nagase, M.; Yamamoto, Y.; Miyazaki, Y.; Yoshino, H. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep., 2015. http://dx.doi.org/10.1179/1351000215Y.0000000026
33. Lange, D.J.; Andersen, P.M.; Remanan, R.; Marklund, S.; Benjamin, D. Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: a phase I pilot study. Amyotroph. Lateral Scler. Frontotemporal. Degener., 2013, 14(3), 199-204. http://dx.doi.org/10.3109/17482968.2012.724074
34. Wright, P.D.; Huang, M.; Weiss, A.; Matthews, J.; Wightman, N.; Glicksman, M.; Brown, R.H., Jr. Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal models. Neurosci. Lett., 2010, 482(3), 188-192. http://dx.doi.org/10.1016/j.neulet.2010.07.020
35. Limpert, A.S.; Mattmann, M.E.; Cosford, N.D. Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS). Beilstein J. Org. Chem., 2013, 9, 717-732. http://dx.doi.org/10.3762/bjoc.9.82
36. Fornai, F.; Longone, P.; Cafaro, L.; Kastsiuchenka, O.; Ferrucci, M.; Manca, M.L.; Lazzeri, G.; Spalloni, A.; Bellio, N.; Lenzi, P.; Modugno, N.; Siciliano, G.; Isidoro, C.; Murri, L.; Ruggieri, S.; Paparelli, A. Lithium delays progression of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S.A., 2008, 105(6), 2052-2057. http://dx.doi.org/10.1073/pnas.0708022105
37. Gill, A.; Kidd, J.; Vieira, F.; Thompson, K.; Perrin, S. No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS. PLoS One, 2009, 4(8), e6489. http://dx.doi.org/10.1371/journal.pone.0006489
38. Aggarwal, S.P.; Zinman, L.; Simpson, E.; McKinley, J.; Jackson, K.E.; Pinto, H.; Kaufman, P.; Conwit, R.A.; Schoenfeld, D.; Shefner, J.; Cudkowicz, M.; Northeast; Canadian Amyotrophic Lateral Sclerosis, c. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol, 2010, 9(5), 481-488. http://dx.doi.org/10.1016/S1474-4422(10)70068-5
39. Wang, L.; Popko, B.; Tixier, E.; Roos, R.P. Guanabenz, which enhances the unfolded protein response, ameliorates mutant SOD1- induced amyotrophic lateral sclerosis. Neurobiol. Dis., 2014, 71, 317-324. http://dx.doi.org/10.1016/j.nbd.2014.08.010
40. Vieira, F.G.; Ping, Q.; Moreno, A.J.; Kidd, J.D.; Thompson, K.; Jiang, B.; Lincecum, J.M.; Wang, M.Z.; De Zutter, G.S.; Tassinari, V.R.; Levine, B.; Hatzipetros, T.; Gill, A.; Perrin, S. Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS. PLoS One, 2015, 10(8), e0135570. http://dx.doi.org/10.1371/journal.pone.0135570
41. McDonnell, M.E.; Vera, M.D.; Blass, B.E.; Pelletier, J.C.; King, R.C.; Fernandez-Metzler, C.; Smith, G.R.; Wrobel, J.; Chen, S.; Wall, B.A.; Reitz, A.B. Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling. Bioorg. Med. Chem., 2012, 20(18), 5642-5648. http://dx.doi.org/10.1016/j.bmc.2012.07.004
42. Grosskreutz, J.; Zoerner, A.; Schlesinger, F.; Krampfl, K.; Dengler, R.; Bufler, J. Kinetic properties of human AMPA-type glutamate receptors expressed in HEK293 cells. Eur. J. Neurosci., 2003, 17(6), 1173-1178. http://dx.doi.org/10.1046/j.1460-9568.2003.02531.x
43. Paizs, M.; Tortarolo, M.; Bendotti, C.; Engelhardt, J.I.; Siklos, L. Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically. Amyotroph Lateral Scler, 2011, 12(5), 340-344. http://dx.doi.org/10.3109/17482968.2011.584627
44. Pascuzzi, R.M.; Shefner, J.; Chappell, A.S.; Bjerke, J.S.; Tamura, R.; Chaudhry, V.; Clawson, L.; Haas, L.; Rothstein, J.D. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler., 2010, 11(3), 266-271. http://dx.doi.org/10.3109/17482960903307805
45. Rothstein, J.D.; Patel, S.; Regan, M.R.; Haenggeli, C.; Huang, Y.H.; Bergles, D.E.; Jin, L.; Dykes Hoberg, M.; Vidensky, S.; Chung, D.S.; Toan, S.V.; Bruijn, L.I.; Su, Z.Z.; Gupta, P.; Fisher, P.B. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 2005, 433(7021), 73-77. http://dx.doi.org/10.1038/nature03180
46. Zhao, Y.; Cudkowicz, M.E.; Shefner, J.M.; Krivickas, L.; David, W.S.; Vriesendorp, F.; Pestronk, A.; Caress, J.B.; Katz, J.; Simpson, E.; Rosenfeld, J.; Pascuzzi, R.; Glass, J.; Rezania, K.; Harmatz, J.S.; Schoenfeld, D.; Greenblatt, D.J. Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis. J. Clin. Pharmacol., 2014, 54(10), 1180-1187. http://dx.doi.org/10.1002/jcph.317
47. Gerber, Y.N.; Privat, A.; Perrin, F.E. Gacyclidine improves the survival and reduces motor deficits in a mouse model of amyotrophic lateral sclerosis. Front Cell Neurosci, 2013, 7, 280. http://dx.doi.org/10.3389/fncel.2013.00280
48. Leng, Y.; Chuang, D.M. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J. Neurosci., 2006, 26(28), 7502-7512. http://dx.doi.org/10.1523/JNEUROSCI.0096-06.2006
49. Ragancokova, D.; Song, Y.; Nau, H.; Dengler, R.; Krampfl, K.; Petri, S. Modulation of synaptic transmission and analysis of neuroprotective effects of valproic Acid and derivates in rat embryonic motoneurons. Cell Mol Neurobiol, 2010, 30(6), 891-900. http://dx.doi.org/10.1007/s10571-010-9518-8
50. Lv, L.; Han, X.; Sun, Y.; Wang, X.; Dong, Q. Valproic acid improves locomotion in vivo after SCI and axonal growth of neurons in vitro. Exp. Neurol., 2012, 233(2), 783-790. http://dx.doi.org/10.1016/j.expneurol.2011.11.042
51. Feng, H.L.; Leng, Y.; Ma, C.H.; Zhang, J.; Ren, M.; Chuang, D.M. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience, 2008, 155(3), 567-572. http://dx.doi.org/10.1016/j.neuroscience.2008.06.040
52. Boll, M.C.; Bayliss, L.; Vargas-Canas, S.; Burgos, J.; Montes, S.; Penaloza-Solano, G.; Rios, C.; Alcaraz-Zubeldia, M. Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis. J. Neurol. Sci., 2014, 340(1-2), 103-108. http://dx.doi.org/10.1016/j.jns.2014.03.005
53. Taniura, H.; Ito, M.; Sanada, N.; Kuramoto, N.; Ohno, Y.; Nakamichi, N.; Yoneda, Y. Chronic vitamin D3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. J. Neurosci. Res., 2006, 83(7), 1179-1189. http://dx.doi.org/10.1002/jnr.20824
54. Gianforcaro, A.; Hamadeh, M.J. Dietary vitamin D3 supplementation at 10x the adequate intake improves functional capacity in the G93A transgenic mouse model of ALS, a pilot study. CNS Neurosci. Ther., 2012, 18(7), 547-557. http://dx.doi.org/10.1111/j.1755-5949.2012.00316.x
55. Gianforcaro, A.; Solomon, J.A.; Hamadeh, M.J. Vitamin D(3) at 50x AI attenuates the decline in paw grip endurance, but not disease outcomes, in the G93A mouse model of ALS, and is toxic in females. PLoS One, 2013, 8(2), e30243. http://dx.doi.org/10.1371/journal.pone.0030243
56. Karam, C.; Barrett, M.J.; Imperato, T.; MacGowan, D.J.; Scelsa, S. Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis. J. Clin. Neurosci., 2013, 20(11), 1550-1553. http://dx.doi.org/10.1016/j.jocn.2013.01.011
57. Pattee, G.L.; Post, G.R.; Gerber, R.E.; Bennett, J.P., Jr. Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment. Amyotroph. Lateral Scler. Other Motor Neuron Disord., 2003, 4(2), 90-95. http://dx.doi.org/10.1080/14660820310012736
58. Liu, J.; Lillo, C.; Jonsson, P.A.; Vande Velde, C.; Ward, C.M.; Miller, T.M.; Subramaniam, J.R.; Rothstein, J.D.; Marklund, S.; Andersen, P.M.; Brannstrom, T.; Gredal, O.; Wong, P.C.; Williams, D.S.; Cleveland, D.W. Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron, 2004, 43(1), 5-17. http://dx.doi.org/10.1016/j.neuron.2004.06.016
59. Pehar, M.; Beeson, G.; Beeson, C.C.; Johnson, J.A.; Vargas, M.R. Mitochondria-targeted catalase reverts the neurotoxicity of hSOD1G(9)(3)A astrocytes without extending the survival of ALSlinked mutant hSOD1 mice. PLoS One, 2014, 9(7), e103438. http://dx.doi.org/10.1371/journal.pone.0103438
60. Carri, M.T.; Ferri, A.; Battistoni, A.; Famhy, L.; Gabbianelli, R.; Poccia, F.; Rotilio, G. Expression of a Cu,Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis induces mitochondrial alteration and increase of cytosolic Ca2+ concentration in transfected neuroblastoma SH-SY5Y cells. FEBS Lett., 1997, 414(2), 365-368. http://dx.doi.org/10.1016/S0014-5793(97)01051-X
61. Martin, L.J. Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis. IDrugs, 2010, 13(8), 568-580. http://dx.doi.org/10.1124/jpet.107.123000
62. Bordet, T.; Buisson, B.; Michaud, M.; Drouot, C.; Galea, P.; Delaage, P.; Akentieva, N.P.; Evers, A.S.; Covey, D.F.; Ostuni, M.A.; Lacapere, J.J.; Massaad, C.; Schumacher, M.; Steidl, E.M.; Maux, D.; Delaage, M.; Henderson, C.E.; Pruss, R.M. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther., 2007, 322(2), 709-720. http://dx.doi.org/10.1124/jpet.107.123000
63. Sunyach, C.; Michaud, M.; Arnoux, T.; Bernard-Marissal, N.; Aebischer, J.; Latyszenok, V.; Gouarne, C.; Raoul, C.; Pruss, R.M.; Bordet, T.; Pettmann, B. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model. Neuropharmacology, 2012, 62(7), 2346-2352. http://dx.doi.org/10.1016/j.neuropharm.2012.02.013
64. Lenglet, T.; Lacomblez, L.; Abitbol, J.L.; Ludolph, A.; Mora, J.S.; Robberecht, W.; Shaw, P.J.; Pruss, R.M.; Cuvier, V.; Meininger, V.; Mitotarget study, g. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur. J. Neurol., 2014, 21(3), 529-536. http://dx.doi.org/10.1111/ene.12344
65. Martin, L.J.; Fancelli, D.; Wong, M.; Niedzwiecki, M.; Ballarini, M.; Plyte, S.; Chang, Q. GNX-4728, a novel small molecule drug inhibitor of mitochondrial permeability transition, is therapeutic in a mouse model of amyotrophic lateral sclerosis. Front. Cell Neurosci., 2014, 8, 433. http://dx.doi.org/10.3389/fncel.2014.00433
66. Zhang, X.; Chen, S.; Song, L.; Tang, Y.; Shen, Y.; Jia, L.; Le, W. MTOR-independent, autophagic enhancer trehalose prolongs motor neuron survival and ameliorates the autophagic flux defect in a mouse model of amyotrophic lateral sclerosis. Autophagy, 2014, 10(4), 588-602. http://dx.doi.org/10.4161/auto.27710
67. Katsumata, R.; Ishigaki, S.; Katsuno, M.; Kawai, K.; Sone, J.; Huang, Z.; Adachi, H.; Tanaka, F.; Urano, F.; Sobue, G. c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis. PLoS One, 2012, 7(9), e46185.
68. Naganska, E.; Taraszewska, A.; Matyja, E.; Grieb, P.; Rafalowska, J. Neuroprotective effect of erythropoietin in amyotrophic lateral sclerosis (ALS) model in vitro. Ultrastructural study. Folia Neuropathol., 2010, 48(1), 35-44.
69. Brettschneider, J.; Widl, K.; Schattauer, D.; Ludolph, A.C.; Tumani, H. Cerebrospinal fluid erythropoietin (EPO) in amyotrophic lateral sclerosis. Neurosci. Lett., 2007, 416(3), 257-260. http://dx.doi.org/10.1016/j.neulet.2007.02.002
70. Grunfeld, J.F.; Barhum, Y.; Blondheim, N.; Rabey, J.M.; Melamed, E.; Offen, D. Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model. Exp. Neurol., 2007, 204(1), 260-263. http://dx.doi.org/10.1016/j.expneurol.2006.11.002
71. Kim, H.Y.; Moon, C.; Kim, K.S.; Oh, K.W.; Oh, S.I.; Kim, J.; Kim, S.H. Recombinant human erythropoietin in amyotrophic lateral sclerosis: a pilot study of safety and feasibility. J. Clin. Neurol., 2014, 10(4), 342-347. http://dx.doi.org/10.3988/jcn.2014.10.4.342
72. Lauria, G.; Dalla Bella, E.; Antonini, G.; Borghero, G.; Capasso, M.; Caponnetto, C.; Chio, A.; Corbo, M.; Eleopra, R.; Fazio, R.; Filosto, M.; Giannini, F.; Granieri, E.; La Bella, V.; Logroscino, G.; Mandrioli, J.; Mazzini, L.; Monsurro, M.R.; Mora, G.; Pietrini, V.; Quatrale, R.; Rizzi, R.; Salvi, F.; Siciliano, G.; Soraru, G.; Volanti, P.; Tramacere, I.; Filippini, G.; Group, E.T.S. Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study. J. Neurol. Neurosurg. Psychiatry, 2015, 86(8), 879-886. http://dx.doi.org/10.1136/jnnp-2014-308996
73. Contestabile, A. Amyotrophic lateral sclerosis: from research to therapeutic attempts and therapeutic perspectives. Curr. Med. Chem., 2011, 18(36), 5655-5665. http://dx.doi.org/10.2174/092986711798347289
74. Iwasaki, Y.; Ikeda, K.; Shiojima, T.; Tagaya, N.; Kobayashi, T.; Kinoshita, M. Bromocriptine prevents neuron damage following inhibition of superoxide dismutase in cultured ventral spinal cord neurons. Neurol. Res., 1997, 19(4), 389-392.
75. Tanaka, K.; Kanno, T.; Yanagisawa, Y.; Yasutake, K.; Hadano, S.; Yoshii, F.; Ikeda, J.E. Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol., 2011, 232(1), 41-52. http://dx.doi.org/10.1016/j.expneurol.2011.08.001
76. Yacila, G.; Sari, Y. Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis. Curr. Med. Chem., 2014, 21(31), 3583-3593. http://dx.doi.org/10.2174/0929867321666140601162710
77. Zhang, Y.; Li, H.; Yang, C.; Fan, D.F.; Guo, D.Z.; Hu, H.J.; Meng, X.E.; Pan, S.Y. Treatment with Hydrogen-Rich Saline Delays Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis. Neurochem. Res., 2015. http://dx.doi.org/10.1007/s11064-015-1750-7
78. Mancuso, R.; del Valle, J.; Modol, L.; Martinez, A.; Granado- Serrano, A.B.; Ramirez-Nunez, O.; Pallas, M.; Portero-Otin, M.; Osta, R.; Navarro, X. Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice. Neurotherapeutics, 2014, 11(2), 419-432.
79. Song, L.; Chen, L.; Zhang, X.; Li, J.; Le, W. Resveratrol ameliorates motor neuron degeneration and improves survival in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Biomed. Res. Int., 2014, 2014, 483501.
80. Tanaka, K.; Kanno, T.; Yanagisawa, Y.; Yasutake, K.; Inoue, S.; Hirayama, N.; Ikeda, J.E. A novel acylaminoimidazole derivative, WN1316, alleviates disease progression via suppression of glial inflammation in ALS mouse model. PLoS One, 2014, 9(1), e87728. http://dx.doi.org/10.1371/journal.pone.0087728
81. Rodrigues, M.C.; Voltarelli, J.C.; Sanberg, P.R.; Borlongan, C.V.; Garbuzova-Davis, S. Immunological aspects in amyotrophic lateral sclerosis. Transl. Stroke Res., 2012, 3(3), 331-340. http://dx.doi.org/10.1007/s12975-012-0177-6
82. Haidet-Phillips, A.M.; Hester, M.E.; Miranda, C.J.; Meyer, K.; Braun, L.; Frakes, A.; Song, S.; Likhite, S.; Murtha, M.J.; Foust, K.D.; Rao, M.; Eagle, A.; Kammesheidt, A.; Christensen, A.; Mendell, J.R.; Burghes, A.H.; Kaspar, B.K. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol., 2011, 29(9), 824-828. http://dx.doi.org/10.1038/nbt.1957
83. Henkel, J.S.; Beers, D.R.; Zhao, W.; Appel, S.H. Microglia in ALS: the good, the bad, and the resting. J. Neuroimmune Pharmacol., 2009, 4(4), 389-398. http://dx.doi.org/10.1007/s11481-009-9171-5
84. Chiu, I.M.; Chen, A.; Zheng, Y.; Kosaras, B.; Tsiftsoglou, S.A.; Vartanian, T.K.; Brown, R.H., Jr.; Carroll, M.C. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl. Acad. Sci. U. S. A., 2008, 105(46), 17913-17918. http://dx.doi.org/10.1073/pnas.0804610105
85. Li, W.; Fotinos, A.; Wu, Q.; Chen, Y.; Zhu, Y.; Baranov, S.; Tu, Y.; Zhou, E.W.; Sinha, B.; Kristal, B.S.; Wang, X. N-acetyl-Ltryptophan delays disease onset and extends survival in an amyotrophic lateral sclerosis transgenic mouse model. Neurobiol. Dis., 2015, 80, 93-103. http://dx.doi.org/10.1016/j.nbd.2015.05.002
86. Noh, M.Y.; Cho, K.A.; Kim, H.; Kim, S.M.; Kim, S.H. Erythropoietin modulates the immune-inflammatory response of a SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS). Neurosci. Lett., 2014, 574, 53-58. http://dx.doi.org/10.1016/j.neulet.2014.05.001
87. Miller, R.G.; Block, G.; Katz, J.S.; Barohn, R.J.; Gopalakrishnan, V.; Cudkowicz, M.; Zhang, J.R.; McGrath, M.S.; Ludington, E.; Appel, S.H.; Azhir, A.; Phase 2 Trial, N.P.I. Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurol. Neuroimmunol. Neuroinflamm., 2015, 2(3), e100. http://dx.doi.org/10.1212/NXI.0000000000000100
88. Stommel, E.W.; Cohen, J.A.; Fadul, C.E.; Cogbill, C.H.; Graber, D.J.; Kingman, L.; Mackenzie, T.; Channon Smith, J.Y.; Harris, B.T. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph. Lateral Scler., 2009, 10(5-6), 393-404. http://dx.doi.org/10.3109/17482960802709416
89. Kiaei, M.; Petri, S.; Kipiani, K.; Gardian, G.; Choi, D.K.; Chen, J.; Calingasan, N.Y.; Schafer, P.; Muller, G.W.; Stewart, C.; Hensley, K.; Beal, M.F. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci., 2006, 26(9), 2467-2473. http://dx.doi.org/10.1523/JNEUROSCI.5253-05.2006
90. Hu, J.H.; Zhang, H.; Wagey, R.; Krieger, C.; Pelech, S.L. Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. J. Neurochem., 2003, 85(2), 432-442. http://dx.doi.org/10.1046/j.1471-4159.2003.01670.x
91. Koh, S.H.; Kim, Y.; Kim, H.Y.; Hwang, S.; Lee, C.H.; Kim, S.H. Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS. Exp. Neurol., 2007, 205(2), 336-346. http://dx.doi.org/10.1016/j.expneurol.2007.03.004
92. Ahn, S.W.; Jeon, G.S.; Kim, M.J.; Shon, J.H.; Kim, J.E.; Shin, J.Y.; Kim, S.M.; Kim, S.H.; Ye, I.H.; Lee, K.W.; Hong, Y.H.; Sung, J.J. Neuroprotective effects of JGK-263 in transgenic SOD1- G93A mice of amyotrophic lateral sclerosis. J. Neurol. Sci., 2014, 340(1-2), 112-116. http://dx.doi.org/10.1016/j.jns.2014.03.008
93. Lee, S.H.; Choi, S.M.; Yang, E.J. Melittin ameliorates the inflammation of organs in an amyotrophic lateral sclerosis animal model. Exp. Neurobiol., 2014, 23(1), 86-92. http://dx.doi.org/10.5607/en.2014.23.1.86
94. Evans, M.C.; Gaillard, P.J.; de Boer, M.; Appeldoorn, C.; Dorland, R.; Sibson, N.R.; Turner, M.R.; Anthony, D.C.; Stolp, H.B. CNStargeted glucocorticoid reduces pathology in mouse model of amyotrophic lateral sclerosis. Acta Neuropathol. Commun., 2014, 2, 66. http://dx.doi.org/10.1186/2051-5960-2-66
95. Tada, S.; Okuno, T.; Hitoshi, Y.; Yasui, T.; Honorat, J.A.; Takata, K.; Koda, T.; Shimagami, H.; Chi-Jing, C.; Namba, A.; Sugimoto, T.; Sakoda, S.; Mochizuki, H.; Kikutani, H.; Nakatsuji, Y. Partial suppression of M1 microglia by Janus kinase 2 inhibitor does not protect against neurodegeneration in animal models of amyotrophic lateral sclerosis. J. Neuroinflam., 2014, 11, 179. http://dx.doi.org/10.1186/s12974-014-0179-2
96. Swarup, V.; Phaneuf, D.; Dupre, N.; Petri, S.; Strong, M.; Kriz, J.; Julien, J.P. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. J. Exp. Med., 2011, 208(12), 2429-2447. http://dx.doi.org/10.1084/jem.20111313
97. Patel, P.; Julien, J.P.; Kriz, J. Early-stage treatment with Withaferin A reduces levels of misfolded superoxide dismutase 1 and extends lifespan in a mouse model of amyotrophic lateral sclerosis. Neurotherapeutics, 2015, 12(1), 217-233. http://dx.doi.org/10.1007/s13311-014-0311-0
98. Wang, L.J.; Lu, Y.Y.; Muramatsu, S.; Ikeguchi, K.; Fujimoto, K.; Okada, T.; Mizukami, H.; Matsushita, T.; Hanazono, Y.; Kume, A.; Nagatsu, T.; Ozawa, K.; Nakano, I. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adenoassociated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J. Neurosci., 2002, 22(16), 6920-6928.
99. Manabe, Y.; Nagano, I.; Gazi, M.S.; Murakami, T.; Shiote, M.; Shoji, M.; Kitagawa, H.; Setoguchi, Y.; Abe, K. Adenovirusmediated gene transfer of glial cell line-derived neurotrophic factor prevents motor neuron loss of transgenic model mice for amyotrophic lateral sclerosis. Apoptosis, 2002, 7(4), 329-334. http://dx.doi.org/10.1023/A:1016123413038
100. Battaglia, G.; Riozzi, B.; Bucci, D.; Di Menna, L.; Molinaro, G.; Pallottino, S.; Nicoletti, F.; Bruno, V. Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD- 1 mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis., 2015, 74, 126-136. http://dx.doi.org/10.1016/j.nbd.2014.11.012
101. Korkmaz, O.T.; Aytan, N.; Carreras, I.; Choi, J.K.; Kowall, N.W.; Jenkins, B.G.; Dedeoglu, A. 7,8-Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis. Neurosci. Lett., 2014, 566, 286-291. http://dx.doi.org/10.1016/j.neulet.2014.02.058
102. Tanaka, H.; Shimazawa, M.; Kimura, M.; Takata, M.; Tsuruma, K.; Yamada, M.; Takahashi, H.; Hozumi, I.; Niwa, J.; Iguchi, Y.; Nikawa, T.; Sobue, G.; Inuzuka, T.; Hara, H. The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis. Sci. Rep., 2012, 2, 573. http://dx.doi.org/10.1038/srep00573
103. Nagahara, Y.; Shimazawa, M.; Tanaka, H.; Ono, Y.; Noda, Y.; Ohuchi, K.; Tsuruma, K.; Katsuno, M.; Sobue, G.; Hara, H. Glycoprotein nonmetastatic melanoma protein B ameliorates skeletal muscle lesions in a SOD1G93A mouse model of amyotrophic lateral sclerosis. J. Neurosci. Res., 2015, 93(10), 1552-1566. http://dx.doi.org/10.1002/jnr.23619